



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 9/50, 9/16, B01J 13/12	A1	(11) International Publication Number: WO 00/62761 (43) International Publication Date: 26 October 2000 (26.10.00)
(21) International Application Number: PCT/CH00/00218 (22) International Filing Date: 14 April 2000 (14.04.00) (30) Priority Data: 99107570.6 15 April 1999 (15.04.99) EP (71) Applicant (for all designated States except US): DEBIO RECHERCHE PHARMACEUTIQUE S.A. [CH/CH]; Case Postale 211, 17, rue des Terreaux, CH-1000 Lausanne 9 (CH). (72) Inventors; and (75) Inventors/Applicants (for US only): VUARIDEL, Evelyne [CH/CH]; Avenue Alfred Cortot 9C, CH-1260 Nyon (CH). ORSOLINI, Piero [CH/CH]; 11, rue de l'Hôpital, CH-1920 Martigny (CH). (74) Agent: ROLAND, André; P.O. Box 1259, 38, rue du Pe- tit-Chêne, CH-1001 Lausanne (CH).		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PROCESS FOR MICROENCAPSULATION OF WATER SOLUBLE SUBSTANCES		
(57) Abstract		
<p>The present invention relates to a process for the preparation of microparticles, with an extremely high encapsulation rate, comprising a water-soluble substance in a biodegradable polymer, said water-soluble substance and said biodegradable polymer being first incorporated in an organic liquid phase comprising at least one organic non-water miscible solvent. The organic phase is poured into an aqueous liquid phase having a volume which is sufficient to dissolve said organic solvent, said aqueous phase containing a surfactant, the resulting organic-aqueous phase being homogenised in order to perform in one single step the microparticle formation and the organic solvent removal. The thus obtained microparticles show surprisingly good agent retention qualities.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Process for microencapsulation of water soluble substances

5 The present invention relates to a process for the preparation of microparticles comprising a water-soluble substance in a biodegradable polymer.

Many different methods of preparation of microspheres are described in
10 the literature (Herrmann et al., European Journal of Pharmaceutics and Biopharmaceutics 45 (1998) 75-82). The methods presently used for the preparation of microspheres from hydrophobic polymers are organic phase separation and solvent removal techniques.

15 The solvent removal techniques can be divided into solvent evaporation, solvent extraction, spray drying and supercritical fluid technology. In solvent evaporation or solvent extraction techniques, a drug containing organic polymer solution is emulsified into an aqueous or another organic solution. The drug is dissolved, dispersed or emulsified in the inner
20 organic polymer solution.

These solvent removal techniques for production of microspheres by evaporation or extraction necessitate the step of preparing a stable emulsion of organic droplets before solvent removal. The size and
25 characteristics of the final microspheres depend on this step during which a stable emulsion in the presence of the solvent is a prerequisite. The proportions of organic solvent and aqueous phase in the solvent removal methods are carefully maintained so as to control the solvent migration in the aqueous phase. Below a certain ratio organic solvent/aqueous phase,
30 the formation of droplets is not possible any more (see H. Sah, "Microencapsulation techniques using ethyl acetate as a dispersed solvent: effects of its extraction rate on the characteristics of PLGA microspheres," Journal of controlled release, 47 (3) 1997, 233-245). In

some methods, solvent is even added to the aqueous phase in order to saturate it and to prevent the solvent migration during the formation of the primary emulsion.

5 Several related patents and published applications describe various aspects of these processes.

EP 0 052 105 B2 (Syntex) describes a microcapsule prepared by the phase separation technique using a coacervation agent such as mineral
10 oils and vegetable oils.

EP 0 145 240 B1 (Takeda) discloses a method for encapsulating a water soluble compound by thickening the inner phase of a W/O emulsion, building a W/O/W and subjecting the emulsion to an "in water drying"
15 process. This method brings different drawbacks such as: the necessity of using a thickening agent to retain the drug, and the multi-step procedure including two emulsification steps and the "in water drying" step.

EP 0 190 833 B1 (Takeda) describes a method for encapsulating a water
20 soluble drug in microcapsules by increasing the viscosity of a primary W/O emulsion to 150-5,000 cp (by the procedure of increasing the polymer concentration in the organic phase or by adjusting the temperatures) prior to formation of a second W/O/W emulsion which is then subjected to "in water drying". The drawbacks of this procedure are the complexity of the
25 necessary steps, including formation of two emulsions (W/O and W/O/W) one after the other, and the step of "in-water drying".

US 5,407,609 (Tice/SRI) describes a microencapsulation process for highly water soluble agents. This process involves the distinct steps of
30 forming a primary O/W emulsion, the external aqueous phase being preferably saturated with polymer solvent. This O/W emulsion is then poured to a large volume of extraction medium in order to extract immediately the solvent. The drawback of this method is that the O/W

emulsion is formed in the presence of the organic solvent in a small volume. The solvent is subsequently removed by extraction in a large aqueous volume. The polymeric droplets are prevented to harden in the primary emulsion, allowing the migration of the drug into the external
5 phase.

WO 95/11008 (Genentech) describes a method for the encapsulation of adjuvants into microspheres. The process comprises the three distinct steps of preparing a primary W/O emulsion, followed by the production of
10 a W/O/W and finally the hardening of the microspheres by extraction of the solvent. As already mentioned above, the drawback of such a method is the complication due to a multi-step procedure separating droplet production from solvent elimination.

15 EP 0 779 072 A1 (Takeda) describes an "in-water drying" method used for the removal of solvent after production of a W/O/W or a O/W emulsion. It is mentioned that the O/W method is preferable for active substances insoluble or sparingly soluble in water.

20 It is an object of the present invention to provide with a new process for the preparation of microparticles comprising water soluble biologically active substances.

25 It is still further an object of the present invention to provide with a new process for the preparation of microparticles of high encapsulating efficiency comprising water soluble biologically active substances.

30 It is further an object of the present invention to provide with a process which allows for a reduction of time of exposure of water soluble active substances to external water phase in the production of microparticles.

It is further an object of the present invention to avoid the formation of specific emulsions, and the problems they have caused as described in

the prior art in the production of microparticles comprising water soluble active substances.

5 To these effects, the present invention relates to a process for the preparation of microparticles with an extremely high encapsulation rate thanks to the optimal reduction of diffusion for the substance to be encapsulated.

10 More precisely, the present invention relates to a process for the preparation of microparticles comprising at least one water-soluble substance in at least one biodegradable polymer, said water-soluble substance and said biodegradable polymer being first incorporated in an organic liquid phase comprising at least one organic non-water miscible solvent, said organic phase being then poured into an aqueous liquid
15 phase having a volume which is sufficient to dissolve said organic solvent, said aqueous phase containing a surfactant, the resulting organic-aqueous phase being homogenised in order to perform in one single step the microparticle formation and the organic solvent removal.

20 The methods available up to now for encapsulating certain compounds and agents, and particularly, water soluble compounds and agents, were not efficient enough for encapsulating water soluble biologically active substances due to the high affinity that water soluble biologically active substances have with the aqueous phase.

25 The present invention has found a solution to this problem by reducing the time required for encapsulating water soluble biologically actives substances, and therefore avoiding the problem of formation of the primary emulsion and solvent removal steps which were far too long and
30 allowed the migration of the water soluble biologically active substances into the external aqueous phase.

The microparticle formation and their hardening is performed in one single step. After homogenisation, the dispersion is directly filtered. The particles are then harvested and optionally lyophilised.

- 5 Using the process of the present invention offers the advantage of providing an encapsulation efficiency greater than 50% or 80%.

Furthermore, in the process of the present invention, it has been surprisingly found that it is possible to obtain microparticles with an
10 extremely high encapsulation efficiency of water soluble active substances using a new one step O/W or W/O/W homogenisation process.

One of the specific features in the process of the present invention is characterised by the fact that no stable primary emulsion comprising
15 organic solvent droplets occurs. Avoiding such a step results in a better retention of the water-soluble substance.

Furthermore, because of the almost instantaneous lack of organic solvent when the polymer precipitates and captures the water-soluble substance,
20 no further emulsion stage is observed. The microparticles can thus be directly harvested after their formation.

Because the microparticle formation and the solvent removal are done together in one single step in this process, the water soluble biologically
25 active substance is quickly kept inside the microparticles which have an impermeable wall. Thereby any diffusion external to the microparticles is at a low level, and the encapsulation rate is very high.

It must also be mentioned that the process of the present invention avoids
30 the steps of solvent extraction and of solvent evaporation.

The organic solvents used in the process of the present invention are non-water miscible solvents such as esters (e.g. ethyl acetate, butyl acetate),

halogenated hydrocarbons (e.g. dichloromethane, chloroform, carbon tetrachloride, chloroethane, dichloroethane, trichloroethane), ethers (e.g. ethyl ether, isopropyl ether), aromatic hydrocarbons (e.g. benzene, toluene, xylene), carbonates (e.g. diethyl carbonate), or the like. Although
5 these solvents are generally classified by the person skilled in the art as non-water miscible solvent, they are actually sparingly miscible in water, having a low solubility in water. For instance, for ethyl acetate and dichloromethane, the solubility is resp. 8.70% and 1.32% (by weight) in water at 20-25°C (see A.K. Doolittle Ed., Properties of individual solvents,
10 in The technology of solvents and plasticizers, chpt. 12. Wiley, New York, 1954, pp. 492-742). One of the preferred solvent is ethyl acetate.

The above-mentioned organic solvents can be used alone or in mixtures of two or more different solvents.

15

The volume of the aqueous phase must be sufficient to dissolve, or extract, the total amount of organic solvent used. If this is not the case, the microparticles cannot be sufficiently hardened. Those "soft" microparticles may therefore melt among each others during the filtration process.

20

Accordingly, the amount of organic solvent is kept as low as possible to get a viscous organic phase and to minimise the necessary volume of the aqueous phase. In all of the following embodiments, the volume of the aqueous phase is chosen to be capable of dissolving at least the complete
25 amount of organic solvent.

30

The maximal value of the ratio solvent/water (w/w) in the present invention should therefore preferably be 0.087 and 0.013 for ethyl acetate and dichloromethane respectively. In the examples given below, the ratio ethyl acetate/aqueous phase ranges from 0.007 to 0.06. The encapsulating efficiency improves if the volume of aqueous phase increases.

A surfactant is added to the aqueous phase in order to keep the precipitating biodegradable polymer in fine independent particles. An ideal surfactant gives a viscosity to the aqueous phase that approaches the viscosity of the organic phase.

5

An electrolyte may also be optionally added to the aqueous solution to create repulsion between the particles and preventing aggregation. As a preferred electrolyte, sodium chloride is used in the aqueous phase and leads to a higher encapsulating efficiency.

10

The aqueous solution can also be buffered to obtain good pH conditions for the drug concerning stability and release.

When a solvent such as ethyl acetate is used, it has been surprisingly found that the encapsulation efficiency is increased when using cold solutions, by optimising the solubility of the solvent in water, by reducing the aqueous solubility of the drug, and by slowing down its diffusion. In other words, the present invention achieves the effect of further reducing the already small amount of diffusion of internal particle substances to the exterior.

20

A water-soluble biologically active substance is dispersed as such or as an aqueous solution into one of the above-mentioned non-miscible organic solvent. In some embodiments of the process, the biologically active substance is present in solid state in the organic phase during the entrapment procedure, thus slowing down the solubilisation into the aqueous liquid phase.

25

The thus obtained liquid organic phase containing the biologically active substance is used to dissolve the biodegradable polymer.

30

The appropriate biodegradable polymers comprise poly(lactides), poly(glycolides), copolymers thereof or other biodegradable polymers

such as other aliphatic polymers, polycitric acid, poly-malic acid, polysuccinates, polyfumarates, poly-hydroxybutyrates, polycaprolactones, polycarbonates, polyesteramides, poly-anhydrides, poly(amino acids), polyorthoesters, polycyano-acrylates, polyetheresters, poly(dioxanone)s, 5 copolymers of polyethylene glycol (PEG), polyorthoesters, biodegradable polyurethanes, polyphosphazenes.

Other biocompatible polymers are polyacrylic acid, poly-methacrylic acid, acrylic acid-methacrylic acid copolymers, dextran stearate, ethylcellulose, 10 acetyl-cellulose, nitrocellulose, etc. These polymers may be homopolymers or copolymers of two or more monomers, or mixtures of the polymers.

The biologically active substance and the polymer can also be 15 incorporated in separate organic phases. The polymer is dissolved in another above-mentioned organic non-water miscible solvent. Preferred solvents include ethyl acetate or dichloromethane. More preferred is when the solvent used to dissolve the polymer is the same solvent as that use for incorporating the biologically active substance. The thus obtained 20 separated organic phases are poured together to form a homogenous organic phase before addition to the aqueous phase.

If the biologically active substance and/or the biodegradable polymer is not or is only slightly soluble in one of the above-mentioned solvent, for 25 instance in the preferred solvent ethyl acetate, a sufficient amount of co-solvents such those comprised among the family of benzyl alcohol, DMSO, DMF, ethyl alcohol, methyl alcohol, acetonitrile and the like, may optionally be used in that purpose.

30 A better encapsulating efficiency can be achieved by an appropriate setting of the physic chemical parameters such as surfactant capacity, viscosity, temperature, ionic strength, pH and buffering potential during the homogenisation of the organic inner phase into the aqueous phase. By

carefully adjusting the production parameters, the precipitating polymer can be surprisingly well formed into homogeneously dispersed particles.

Preferably, the amount of solvent used to dissolve the biodegradable polymer is kept to a minimum in order to be soluble as quickly as possible (most preferably at once) in the aqueous phase. If the amount of solvent is high, the amount of aqueous phase has to be too large on a practical point of view.

10 The concentration of polymer in the organic phase is adjusted to 5-90% (by weight), preferably between about 10 and 50%, depending on the polymer and solvent used.

In the case that the concentration of polymer in the organic solvent is high, 15 the viscosity of this phase, depending on the polymer used, may be increased.

The viscosity of the polymer solution may be comprised between 1000 and 40,000 centipoise (cp) (Brookfield viscosity), more preferably between 20 2,000 and 30,000 cp, even more preferable between 3,000 and 20,000 cp.

Using solvents like ethyl acetate for dissolving the polymer, the solubility of the solvent in the aqueous phase is increased by lowering the 25 temperature of both, the organic and the aqueous phases, accelerating the solvent migration and therefore also the encapsulation rate.

In process of the present invention, the temperature of the organic phase ranges between about -10°C and 30°C , and preferably between about 30 0°C and 10°C . For ethyl acetate, the temperature ranges preferably between about 2°C and 5°C . The temperature of the polymeric organic phase and the temperature of the aqueous phase are the same or

different and are adjusted in order to increase the solubility of the solvent in the aqueous phase.

The obtained organic phase for use as the inner polymer and biologically
5 active substance containing phase is added to a aqueous outer phase under a homogenisation procedure to give microparticles.

For the homogenisation procedure, a method of creating dispersion is used. This dispersion can be realised for example with any apparatus
10 capable of shaking, mixing, stirring, homogenising or ultrasonication.

Different agents influencing the physico-chemical characteristics of the resultant medium may be added. For instance, surfactants, such as for example an anionic surfactant (e.g. sodium oleate, sodium stearate,
15 sodium lauryl sulfate), a nonionic surfactant (e.g. polyoxyethylene-sorbitant fatty acid ester (Tween 80, Tween 60, products available from Atlas Powder Co, U.S.A.), a polyoxyethylene castor oil derivative (HCO-60, HCO-50, products available from Nikko Chemicals, Japan)), polyvinyl pyrrolidone, polyvinyl alcohol, carboxymethyl-cellulose, lecithin or gelatine.

20

In specific embodiments of the present invention, a surfactant comprised among the family of anionic, non-ionic agents or other agents capable of reducing the surface tension of the polymeric dispersion can be added. Suitably, therefore, are nonionic surfactants such as Tween (for example
25 Tween 80), anionic surfactants, nonionic surfactant like polyvinyl alcohol or others. These surfactants can, in general, be used alone or in combination with other suitable surfactants. The concentration of the surfactant is selected in order to disperse and stabilise the polymer particles, and possibly also to give a viscosity approaching the viscosity of
30 the organic phase.

The preferred concentration of the surfactant in the aqueous phase ranges therefore between about 0.01-50% (by weight), preferably between

about 5 and 30%. The viscosity depending on the surfactant used and on its concentration ranges between about 1,000-8,000 cp (Brookfield viscosity), preferably about 3,000-5,000 cp.

- 5 Optionally salts comprised among the family of sodium chloride, potassium chloride, carbonates, phosphates and the like can be added to the aqueous phase to adjust ionic strength and to create a Zeta potential between the polymer particles, leading to particle repulsion.
- 10 Additional buffering agents may be added to the aqueous phase to maintain a specific pH. So, the internal aqueous phase may be supplemented with a pH regulator for retaining stability or solubility of the biologically active substance, such as carbonic acid, acetic acid, oxalic acid, citric acid, phosphoric acid, hydrochloric acid, sodium hydroxide,
- 15 arginine, lysine or a salt thereof. The pH of the formulations of this invention is generally about 5 to 8, preferably about 6.5 to 7.5.

The temperature of the aqueous phase can be adjusted to the temperature of the inner organic phase. The temperature range is from

20 about -10°C to 30°C , more preferably between 0° and 10°C and even more preferably from between 2°C and 5°C .

The microparticles of the present invention can be prepared in any desired size, ranging from $1\mu\text{m}$ to about $500\mu\text{m}$, by varying the parameters such

25 as polymer type and concentration in the organic phase, volumes and temperature of the organic and aqueous phase, surfactant type and concentration, homogenisation time and speed. The mean particle size of the microparticles ranges generally from 10 to $200\mu\text{m}$, more preferably from 20 to $200\mu\text{m}$, even more preferably from 30 to $150\mu\text{m}$.

30

A number of water soluble active substances can be encapsulated by the process of the present invention.

Preferably, the encapsulated soluble substance is a peptide, a polypeptide, a protein and their related pharmaceutically acceptable salts. The salt of peptide is preferably a pharmacologically acceptable salt. Such salts include salts formed with inorganic acids (e.g. hydrochloric acid, sulphuric acid, nitric acid), organic acids (e.g. carbonic acid, bicarbonic acid, succinic acid, acetic acid, propionic acid, trifluoroacetic acid) etc. More preferably, the salt of peptide is a salt formed with an organic acid (e.g. carbonic acid, bicarbonic acid, succinic acid, acetic acid, propionic acid, trifluoroacetic acid) with greater preference given to a salt formed with acetic acid. These salts may be mono-through tri-salts.

Examples of water soluble active substances which can be encapsulated in the present invention include, but are not limited to, peptides, polypeptides and proteins such as luteinizing hormone releasing hormone (LHRH) or derivatives of LHRH comprising agonists or antagonists, melanocyte stimulating hormone (MSH), thyrotropin releasing hormone (TRH), thyroid stimulating hormone (TRH), follicle stimulating hormone (FSH), human chorionic gonadotropin (HCG), parathyroid hormone (PTH), human placental lactogen, insulin, somatostatin and derivatives, gastrin, prolactin, adreno-corticotrophic hormone (ACTH), growth hormones (GH), growth hormone releasing hormone (GHRH), growth hormone releasing peptide (GHRP), calcitonin, oxytocin, angiotensin, vasopressin, enkephalins, endorphin, enkephalin, kyotorphine, interferons, interleukins, tumor necrosis factor (TNF), erythropoietin (EPO), colony stimulating factors (G-CSF, GM-CSF, M-CSF), thrombopoietin (TPO), platelet derived growth factor, fibroblast growth factors (FGF), nerve growth factors (NGF), insulin like growth factors (IGF), amylin peptides, leptin, RGD peptides, bone morphogenic protein (BMP), substance P, serotonin, GABA, tissue plasminogen activator (TPA), superoxide dismutase (SOD), urokinase, kallikrein, glucagon, human serum albumin, bovine serum albumin, gamma globulin, immunomodulators (EGF, LPS), blood coagulating factor, lysozyme chloride, polymyxin B, colistin, gramicidin, bacitracin and the like.

A number of other unlimiting example of water soluble substances or particularly a water soluble form of the following substances can be encapsulated by the process of the present invention.

5

These substances comprise for instance anticancer drugs such as actinomycin D, bleomycin, busulfan, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, dacarbazine, daunorubicin, doxorubicin, estramustine, etoposide, 10 floxuridine, fludarabine, fluorouracil, hexamethylmelamine, hydroxyurea, idarubicin, ifosfamide, asparaginase, lomustine, mechlorethamine, melphalan, mercaptopurine, methotrexate, mithramycin, mitomycin C, mitotane, mitozantrone, oxaliplatin, pentostatin, procarbazine, streptozocin, teniposide, thioguanine, thiopeta, vinblastine, vincristine and 15 the like; antibiotics such as tetracyclines, penicillins, sulfisoxazole, ampicillin, cephalosporins, erythromycin, clindamycin, isoniazid, amikacin, chloramphenicol, streptomycin, vancomycin and the like.

Other examples of such substances comprise antivirals such as acyclovir, 20 amantadine, and the like; antipyretics, analgesics and antiinflammatory agents include acetaminophen, acetylsalicylic acid, methylprednisolone, ibuprofen diclofenac sodium, indomethacin sodium, flufenamate sodium, pethidine hydrochloride, levorphanol tartrate, morphine hydrochloride, oxymorphone and the like; anesthetics such as lidocaine, xylocaine and 25 the like; antiulcer agents include metoclopramide, ranitidine hydrochloride, cimetidine hydrochloride, histidine hydrochloride, and the like anorexics such as dexedrine, phendimetrazine tartrate, and the like; antitussives such as noscapine hydrochloride, dihydrocodeine phosphate, ephedrine hydrochloride, terbutaline sulfate, isopreterenol hydrochloride, salbutamol 30 sulfate, and the like; antiepileptics such as acetazolamide sodium, ethosuximide, phenytoin sodium, diazepam and the like; antidepressants such as amoxapine, isocarboxamide, phenelzine sulfate, clomipramine,

noxiptilin, imipramine, and the like anticoagulants such as heparin or warfarin, and the like.

Other unlimiting examples comprise sedatives such as chlorpromazine
5 hydrochloride, scopolamine methylbromide, antihistaminics such as diphenhydramine hydrochloride, ketotifen fumarate, chlorpheniramine maleate, methoxy-phenamine hydrochloride and the like.

Other unlimiting examples comprise cardiotonics such as etilefrine
10 hydrochloride, aminophylline and the like; antiasthmatics such as terbutaline sulfate, theophylline, ephedrine, and the like; antifungals such as amphotericin B, nystatin, ketoconazole, and the like; antiarrhythmic agents such as propranolol hydrochloride, alprenolol hydrochloride, bufetolol hydrochloride, oxyprenolol hydrochloride and the like;
15 antitubercular agents such as isoniazid, ethambutol, and the like; hypotensive, diuretic agents such as captopril, ecarazine, mecamlamine hydrochloride, clonidine hydrochloride, bunitrolol hydrochloride and the like; hormones such as prednisolone sodium sulfate, betamethasone sodium phosphate, hexestrol phosphate, dexamethasone sodium sulfate
20 and the like; antigens from bacteria, viruses or cancers, antidiabetics such as glipizide, phenformin hydrochloride, buformin hydrochloride, glymidine sodium, methformin, and the like; cardiovascular agents such as propanolol hydrochloride, nitroglycerin, hydralazine hydrochloride, prazosin hydrochloride and the like; diuretics such as spironolactone,
25 furosemide and the like; and enzymes, nucleic acids, plant extracts, anti-malarials, psychotherapeutics, hemostatic agents, etc.

The examples that follow are set forth as an aid in understanding the present invention, and provide some examples of the many embodiments
30 that are potentially available for the present invention. They are not intended to limit the scope of the invention.

Example 1

62.5 mg of D-Trp⁶-LHRH acetate (Triptorelin acetate) was added to 20g of ethyl acetate. The peptide particles were reduced in size with a small size dispersing apparatus. This peptide suspension was added to 2 g of poly(D-L-lactide-co-glycolide) (PLGA) with a ratio of lactide to glycolide of 50 :50 and a weight average molecular weight of 45,000. The mixture was stirred at room temperature until the polymer was dissolved and then placed still at 4°C. The Brookfield viscosity of this solution was 15'500cp. (15.5 Pas).

This organic phase was poured into 675 g of aqueous phase containing 20% (w/w) of Tween 80 and 7g of sodium chloride and having a temperature of 4°C. The homogenisation was performed with a Polytron homogeniser during 3 minutes.

The microparticles were collected right after the end of the homogenisation step by filtration. The microparticles were then vacuum dried at room temperature.

The entrapment efficiency was 93%, the mean particle size was 52µm, and the residual ethyl acetate was 183ppm (as determined by GC-MS).

Example 2

1250 mg of D-Trp⁶-LHRH acetate (Triptorelin acetate) was added to 200g of ethyl acetate. The peptide particles were reduced in size with a small size dispersing apparatus.

40 g of poly(D-L-lactide-co-glycolide) (PLGA) with a ratio of lactide to glycolide of 50 : 50 and a weight average molecular weight of 45,000 were dissolved in 200g of ethyl acetate at room temperature.

Both organic phases were poured together and stirred briefly on a magnetic stirrer. The suspension was then let to stand at 4°C until use. This organic phase was poured into 7kg of aqueous phase containing
5 20% (W/W) of Tween 80 in 67mM phosphate buffer pH 7.4 and 70 g of sodium chloride and having a temperature of 4°C. The homogenisation was performed during 5 minutes.

10 The microparticles were collected right after the end of the homogenisation step by filtration. The microparticles were then vacuum dried at room temperature.

The entrapment efficiency was 76% and the mean particle size was 150µm.

15

Example 3

125 mg of bovine serum albumin was added to 20g of ethyl acetate. The
20 solid protein particles were reduced in size with a small size dispersing apparatus. This protein suspension was added to 2 g of poly(D-L-lactide-co-glycolide) (PLGA) with a ratio of lactide to glycolide of 50 :50 and a weight average molecular weight of 45,000. 20g of additional ethyl acetate were added. The mixture was stirred at room temperature until the
25 polymer was dissolved and then placed still at 4°C.

This organic phase was poured into 675 g of aqueous phase containing 20% (W/W) of Tween 80 in 67mM phosphate buffer pH 7.4 and 7g of sodium chloride and having a temperature of 7°C. The homogenisation
30 was performed with a Polytron during 3 minutes.

The microparticles were collected right after the end of the homogenisation step by filtration.

The microparticles were then vacuum dried at room temperature. The entrapment efficiency was 76% and the mean particle size was 74 μ m.

5

Example 4

125 mg of D-Trp⁶-LHRH acetate (Triptorelin acetate) was added to 5g of ethyl acetate. The peptide particles were reduced in size with a small size
10 dispersing apparatus.

4 g of poly(D-L-lactide) polymer were added to this peptide suspension. The mixture was stirred at room temperature until the polymer was dissolved and then placed still at 8°C.

15

This organic phase was poured into 675 g of aqueous phase containing 20% (W/W) of Tween 80 in 67mM phosphate buffer pH 7.4 and 7 g of sodium chloride and having a temperature of 5°C. The homogenisation was performed with a homogeniser during 3 minutes.

20

The microparticles were collected right after the end of the homogenisation step by filtration. The microparticles were then vacuum dried at room temperature. The entrapment efficiency was 57% and the mean particle size was 30 μ m.

25

Example 5

125 mg of D-Trp⁶-LHRH acetate (Triptorelin acetate) was dissolved in
30 1.5g of water.

4 g of poly(D-L-lactide-co-glycolide) (PLGA) with a ratio of lactide to glycolide of 50 :50 and a weight average molecular weight of 45,000 were

dissolved in 40g of ethyl acetate at room temperature. This organic phase was cooled to 4°C.

5 The aqueous phase was homogenised into the organic phase. This W/O preparation was poured into 680 g of aqueous phase containing 20% (w/w) of polyoxyethylene sorbitan fatty acid ester (Tween 80) and 7 g of sodium chloride and having a temperature of 4°C. The homogenisation was performed and the microparticles were collected by filtration. The microparticles were then vacuum dried at room temperature.

10

The entrapment efficiency was 80% and the mean particle size was 60µm.

Example 6

15

125 mg of vapreotide acetate was dissolved in 2g of water.

4 g of poly(D-L-lactide-co-glycolide) (PLGA) with a ratio of lactide to glycolide of 50 :50 and a weight average molecular weight of 45,000 were
20 dissolved in 40g of ethyl acetate at room temperature. This organic phase was cooled to 4°C.

The aqueous phase was homogenised into the organic phase. This W/O preparation was poured into 800 g of aqueous phase containing 20%
25 (w/w) of polyoxyethylene sorbitan fatty acid ester (Tween 80) and 8 g of sodium chloride and having a temperature of 4°C. The homogenisation was performed and the microparticles were collected by filtration. The microparticles were then vacuum dried at room temperature.

30 The entrapment efficiency was 76% and the mean particle size was 55µm.

Claims

1. A process for the preparation of microparticles comprising at least one water-soluble substance in at least one biodegradable polymer, said water-soluble substance and said biodegradable polymer being first incorporated in an organic liquid phase comprising at least one organic non-water miscible solvent, **characterised** in that said organic phase is poured into an aqueous liquid phase having a volume which is sufficient to dissolve said organic solvent, said aqueous phase containing a surfactant, the resulting organic-aqueous phase being homogenised in order to perform in one single step the microparticle formation and the organic solvent removal.
2. The process of claim 1 wherein the aqueous phase contains an amount of an electrolyte.
3. The process of claim 2 wherein the electrolyte is sodium chloride.
4. The process according to any of previous claims wherein the organic solvent is ethyl acetate.
5. The process according to claim 4 wherein the volumic ratio organic solvent/aqueous phase is comprised between 0.007 and 0.06.
6. The process according to claim 4 or 5 wherein the temperature of the organic phase is comprised between 2°C and 5°C.

5 7. The process according to any of the previous claims wherein the water-soluble substance is a peptide, a polypeptide, a protein and the related pharmaceutically acceptable salts thereof.

10 8. The process according to claim wherein the peptide is a luteinizing hormone releasing hormone (LHRH) or a derivative thereof.

9. The process according to any of the previous claims wherein the surfactant is Tween 80.

15 10. Microparticles obtained according to the process of claim 1.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH 00/00218

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/50 A61K9/16 B01J13/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K B01J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, MEDLINE, EMBASE, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 257 909 A (DEBIO RECH PHARMA SA) 27 January 1993 (1993-01-27) page 5, line 24 -page 5, line 28; examples 1-8 ---	1-10
X	GB 2 234 896 A (SANDOZ LTD) 20 February 1991 (1991-02-20) examples 1-3,11 ---	1-10
X	EP 0 585 151 A (RHONE MERIEUX) 2 March 1994 (1994-03-02) examples 1-3 ---	1-10
X	WO 97 41837 A (JANSSEN PHARMACEUTICA NV ;ALKERMES INC (US)) 13 November 1997 (1997-11-13) example 1 --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 July 2000

Date of mailing of the international search report

11/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pilling, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CH 00/00218

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 297 476 A (FARBENFABRIKEN BAYER AG) 22 November 1972 (1972-11-22) example 1 ---	1-10
X	US 5 238 714 A (WALLACE MICHAEL ET AL) 24 August 1993 (1993-08-24) column 2, line 58 -column 2, line 63; example 1 ---	1-10
X	US 3 691 090 A (KITAJIMA MASAO ET AL) 12 September 1972 (1972-09-12) examples 1-9 ---	1-10
X	US 3 960 757 A (MORISHITA MASATAKA ET AL) 1 June 1976 (1976-06-01) examples 1-15 -----	1-10

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/CH 00/00218

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2257909 A	27-01-1993	CH 683149 A	31-01-1994
		AT 403348 B	26-01-1998
		AT 148992 A	15-06-1997
		AU 651711 B	28-07-1994
		AU 2043692 A	28-01-1993
		AU 652844 B	08-09-1994
		AU 2043792 A	28-01-1993
		BE 1005696 A	21-12-1993
		BE 1005697 A	21-12-1993
		BR 9205375 A	08-03-1994
		CA 2074320 A,C	23-01-1993
		CA 2074322 A	23-01-1993
		CH 683592 A	15-04-1994
		WO 9301802 A	04-02-1993
		CN 1070344 A	31-03-1993
		CZ 9300660 A	19-01-1994
		DE 4223282 A	28-01-1993
		DE 4223284 A	28-01-1993
		DE 9219084 U	25-09-1997
		DK 93892 A	23-01-1993
		DK 93992 A	23-01-1993
		ES 2037621 B	01-02-1994
		ES 2050070 A	01-05-1994
		FI 923320 A	23-01-1993
		FI 923321 A	23-01-1993
		FR 2679450 A	29-01-1993
		FR 2680109 A	12-02-1993
		GB 2257973 A,B	27-01-1993
		GR 1001446 B	30-12-1993
		GR 92100323 A,B	24-05-1993
		HR 920229 A	30-04-1996
		HU 64234 A	28-12-1993
		IE 69967 B	16-10-1996
		IE 71199 B	12-02-1997
		IL 102590 A	13-07-1997
		IL 102591 A	10-06-1997
		IT 1259891 B	28-03-1996
		IT 1259892 B	28-03-1996
		JP 6172208 A	21-06-1994
		JP 2842736 B	06-01-1999
		JP 5221855 A	31-08-1993
		LU 88150 A	15-02-1993
		LU 88151 A	15-02-1993
		MX 9204268 A	31-03-1994
		NL 9201309 A	16-02-1993
		NL 9201310 A	16-02-1993
		NO 304136 B	02-11-1998
		NO 304057 B	19-10-1998
		NZ 243643 A	26-10-1993
		PL 298504 A	10-01-1994
GB 2234896 A	20-02-1991	AT 406225 B	27-03-2000
		AT 144090 A	15-08-1999
		AU 687553 B	26-02-1998
		AU 2332195 A	07-09-1995
		AU 4198593 A	23-09-1993
		AU 4198693 A	23-09-1993
		AU 641407 B	23-09-1993

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/CH 00/00218

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2234896 A		AU 5874690 A	10-01-1991
		BE 1004486 A	01-12-1992
		CA 2020477 A	08-01-1991
		CH 685230 A	15-05-1995
		CH 686226 A	15-02-1996
		CH 686252 A	15-02-1996
		CY 1844 A	08-03-1996
		CY 1965 A	04-07-1997
		DE 4021517 A	17-01-1991
		DK 162590 A	08-01-1991
		FI 991120 A	17-05-1999
		FI 20000059 A	12-01-2000
		FI 20000060 A	12-01-2000
		FR 2649319 A	11-01-1991
		GB 2265311 A,B	29-09-1993
		GR 90100513 A,B	10-12-1991
		HK 97695 A	23-06-1995
		HK 197496 A	08-11-1996
		HU 54037 A	28-01-1991
		HU 9500523 A	30-10-1995
		IE 64216 B	26-07-1995
		IE 64411 B	09-08-1995
		IL 94983 A	17-08-1999
		IT 1241460 B	17-01-1994
		JP 2931773 B	09-08-1999
		JP 7285853 A	31-10-1995
		JP 7309897 A	28-11-1995
		JP 2112513 C	21-11-1996
		JP 3068511 A	25-03-1991
		JP 8032624 B	29-03-1996
		JP 8198771 A	06-08-1996
		LU 87764 A	11-03-1992
		NL 9001537 A	01-02-1991
		NO 302928 B	11-05-1998
		NO 960075 A	08-01-1991
		NO 960076 A	08-01-1991
		NO 983923 A	08-01-1991
		NZ 234384 A	26-05-1994
		PT 94628 A,B	20-03-1991
		SE 512992 C	12-06-2000
		SE 9002364 A	08-01-1991
		SG 9590737 A	01-09-1995
		US 5639480 A	17-06-1997
EP 0585151 A	02-03-1994	FR 2693905 A	28-01-1994
		AT 188382 T	15-01-2000
		AU 675788 B	20-02-1997
		AU 4202293 A	10-02-1994
		CA 2100925 A	28-01-1994
		DE 69327491 D	10-02-2000
		ES 2141756 T	01-04-2000
		JP 6087758 A	29-03-1994
		NZ 248207 A	27-02-1996
		US 5540937 A	30-07-1996
WO 9741837 A	13-11-1997	AU 2897297 A	26-11-1997
		BG 102854 A	31-05-1999
		BR 9709217 A	10-08-1999

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/CH 00/00218

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9741837 A		CA 2251987 A	13-11-1997
		CN 1226821 A	25-08-1999
		CZ 9803591 A	17-03-1999
		EP 0904063 A	31-03-1999
		JP 2000503663 T	28-03-2000
		NO 984808 A	06-01-1999
		PL 329720 A	12-04-1999
		SK 154198 A	07-05-1999
		US 5916598 A	29-06-1999
		US 5792477 A	11-08-1998
GB 1297476 A	22-11-1972	AT 310127 B	15-08-1973
		BE 763791 A	02-08-1971
		CA 922588 A	13-03-1973
		CH 549408 A	31-05-1974
		CS 158290 B	15-10-1974
		DE 2010116 A	16-09-1971
		ES 388917 A	16-02-1974
		FR 2084200 A	17-12-1971
		IL 36222 A	29-08-1973
		JP 53044424 B	29-11-1978
		SU 379074 A	18-04-1973
		TR 16847 A	01-07-1973
		ZA 7101052 A	27-10-1971
US 5238714 A	24-08-1993	AT 136811 T	15-05-1996
		AU 659622 B	25-05-1995
		AU 9076691 A	28-04-1992
		CA 2092551 A	03-04-1992
		DE 69118902 D	23-05-1996
		EP 0553299 A	04-08-1993
		JP 6504716 T	02-06-1994
		WO 9205866 A	16-04-1992
		US 5484584 A	16-01-1996
US 3691090 A	12-09-1972	JP 49033738 B	09-09-1974
		AT 310126 B	15-08-1973
		BE 744162 A	15-06-1970
		CA 925380 A	01-05-1973
		CH 550606 A	28-06-1974
		CS 162703 B	15-07-1975
		DE 2001726 A	23-07-1970
		DK 131548 B	04-08-1975
		FR 2032314 A	27-11-1970
		GB 1275712 A	24-05-1972
		NL 7000343 A	20-07-1970
US 3960757 A	01-06-1976	DE 2332640 A	16-01-1975
		GB 1413186 A	12-11-1975